scispace - formally typeset
Z

Zbigniew Gaciong

Researcher at Medical University of Warsaw

Publications -  190
Citations -  6768

Zbigniew Gaciong is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Transplantation & Blood pressure. The author has an hindex of 33, co-authored 189 publications receiving 5130 citations. Previous affiliations of Zbigniew Gaciong include University of Warsaw.

Papers
More filters
Journal ArticleDOI

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Bin Zhou, +1144 more
- 11 Sep 2021 - 
TL;DR: In this article, a Bayesian hierarchical model was used to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control).
Journal ArticleDOI

Effect of valsartan on the incidence of diabetes and cardiovascular events.

John J.V. McMurray, +53 more
- 22 Apr 2010 - 
TL;DR: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.
Journal ArticleDOI

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice

Katrina Podsypanina, +17 more
- 28 Aug 2001 - 
TL;DR: It is shown that transformed cells of PTEN+/− mice have elevated levels of phosphorylated Akt and activated p70/S6 kinase associated with an increase in proliferation and that inhibition of these proteins may be therapeutic for cancer patients with deranged PI3K signaling.
Journal ArticleDOI

Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm

Shunichi Homma, +536 more
- 16 May 2012 - 
TL;DR: There was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin among patients with reduced LVEF who were in sinus rhythm, and a reduced risk of ischemic stroke withwarfarin was offset by an increased risk of major hemorrhage.
Journal ArticleDOI

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, +18 more
- 28 Oct 2017 - 
TL;DR: There was a monotonic relationship between achieved LDL cholesterol and major cardiovascular outcomes down to LDL-cholesterol concentrations of less than 0·2 mmol/L and there were no safety concerns with very low cholesterol concentrations over a median of 2·2 years of follow-up.